Skip to main content

FIIs raise stake in over 200 stocks in June quarter, 17 gain 100-400% YTD

 The pandemic has opened new doors to business opportunities for some of these companies, suggest experts. The companies which have gained momentum are likely to benefit the most from the COVID.

 

In June quarter, foreign institutional investors (FIIs) pumped in over Rs 14,000 crore in the cash segment of equity markets, and raised stake in over 200 companies on the BSE.

Out of these, as many as 106 stocks gave positive returns while the rest recorded a fall of up to 70 percent in 2020 year-to-date, data from AceEquity showed.

Most of the stocks in which FIIs have raised stake are from the small & midcap space.

From 106 names that gave positive returns, 17 stocks more than doubled investor wealth in 2020 year-to-date. These include Granules India, Dixon Technologies, Adani Green, Laurus Labs, Aarti Drugs and IOL Chemicals.

The pandemic has opened new doors to business opportunities for some of these companies, suggest experts. The companies which have gained momentum are likely to benefit the most from the COVID situation or government policies.


Growth push? 

Foreign investors usually trust largecaps stocks due to liquidity, and being leaders in their own domain. But, experts feel that FIIs may have tweaked the strategy to accommodate small & midcaps in which they could see the potential for growth.

History suggests that they (FIIs) remain very selective when it comes in to investing as tons of research goes before they increase or decrease their stale. An increase in stake in some of these companies is indeed a positive sign.

“FIIs normally invest in large caps due to liquidity and market cap factor. However, if the story is compelling and future growth outlook is very high and scalable then we do see FIIs investing in such select mid-caps,” Rusmik Oza, Executive Vice President, Head of Fundamental Research at Kotak Securities told Moneycontrol.

“It is rare to see FIIs investing in small companies not having a scalable business model. Some of the names mentioned like Dixon, Aarti Drugs, Laurus Labs have a scalable business model and hence FIIs can take a longer view in anticipation of stock moving from a smaller mid-cap company to a larger mid-cap company in future,” he said.

Oza further added that FIIs do chase selective growth stocks in emerging markets otherwise they have enough large valued companies trading in the developed markets itself.

Follow US On Facebook - Click Here

Decrease in stake:

There are more than 600 companies in which FIIs decreased their stake sequentially in the June quarter, according to data collated from AceEquity.

Out of 632 companies, 18 companies in which FIIs reduced stake rose more than 100 percent so far in 2020 that include names like Aalok Industries, Best Agrolife, JMT Auto, Shilpa Medicare, Alkyl Amines etc. among others.


A decrease in FIIs holding could be considered a negative sign but investors should filter the reason behind fall in the holding before making a decision to either buy or sell, suggest experts.

“FII’s buying or selling the stock should not be the basis for investors to buy or sell the stock at the first instance. FII’s selling their stake at sometimes can be part of their rebalancing strategy,” Gaurav Garg, Head of Research at CapitalVia Global Research Limited told Moneycontrol.

“It seems like the FII’s have reduced stake in most of the companies based on valuations and would buy again when valuations become attractive. Apart from FII’s interest in analyzing company’s cash flows, balance sheet and growth prospects are also extremely important,” he said.

Garg further added that investors are advised to perform a detailed analysis of the stock before they invest. A good business driven by a good set of people will always deliver good returns in the longer run.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com/SD Solutions advises users to check with certified experts before taking any investment decisions.

Source - Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more